[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"roux-en-y-gastric-bypass\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:roux-en-y-gastric-bypass":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100630138","feasibility-and-health-economic-evaluation-of-remote-clinical-monitoring-enabling-same-day-discharge-after-bariatric-surgery-100630138",false,"NCT07483775","Feasibility and Health-economic Evaluation of Remote Clinical Monitoring Enabling Same-day Discharge After Bariatric Surgery","Feasibility and Health-economic Evaluation of Remote Clinical Monitoring Enabling Same-day Discharge After Bariatric Surgery: a Randomized Controlled Pilot Feasibility Trial","REMABS","Inclusion Criteria:\n\n* 18-65 years old\n* Undergoing scheduled ambulatory Roux en Y Gastric Bypass\n* ASA score I or II\n* Competent to provide informed consent\n* Surgery is planned in the morning\n* Fluent in Dutch\n* Owning a smartphone or having a caregiver who can assist\n* Cognitively capable of understanding the study and using the remote wearables\n* An informal caregiver is available following hospital discharge, more specifically during the remainder of the day of surgery (Postoperative day POD 0 and throughout POD 1)\n\nExclusion Criteria:\n\n* Presence of coagulation abnormalities or use of anticoagulant therapy\n* History of major abdominal surgeries, including laparotomy\n* Absence of informed consent or request not to participate in the study","ALL","18 Years","65 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The ultimate goal of this research is to optimize care for patients undergoing laparoscopic bariatric surgery while alleviating pressure on hospital resources and staff. Furthermore, the study aims to generate policy-relevant data that can inform policymakers and healthcare providers in developing funding models and care pathways that balance safety, efficiency, and cost-effectiveness. This could support a broader implementation of ambulatory bariatric surgery without compromising quality of care.",[28],"Roux-en Y Gastric Bypass",[30,31,32],"feasibility study","remote monitoring","bariatic surgery","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":22},"2026-05-05",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Jessa Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100615005","gastro-intestinal-digestion-and-physiology-after-bariatric-surgery-100615005","NCT07286968","Gastro-Intestinal Digestion and Physiology After Bariatric Surgery","GIBa","Inclusion Criteria:\n\nParticipants eligible for inclusion in this Investigation have to meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Age: 18-65 years\n\n   Specific inclusion criteria for the different patient populations:\n\n   Patients with obesity:\n3. Body Mass Index: \\> 30 kg\u002Fm2\n\n   Patients after bariatric surgery:\n4. Surgery: at least one year after Roux-en-Y gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\nParticipants eligible for this Investigation must not meet any of the following criteria:\n\n1. Patient has history of more than one bariatric surgery\n2. Patient has a waist circumference \\> 125.6 cm\n3. Patient had gastrointestinal surgery in the past three months\n4. Patient has a pacemaker, defibrillator, infusion pump, or other portable or implanted electromedical device\n5. Patient had frequent exposure to X-rays in the past year\n6. Patient has swallowing disorders, among others: dysphagia for food or pills, any oropharyngeal or oesophageal stricture, anxiety or functional abnormality\n7. Patient has Crohn's disease or Diverticulitis\n8. Patient has gastrointestinal strictures, fistulas or physiological\u002Fmechanical obstructions\n9. Patient has gastric bezoar\n10. Patient has a history of complex bowel resection or known abdominal adhesions\n11. Patient has short bowel syndrome or ostomy\n12. Patient has currently ongoing infections\n13. Patient is planned to undergo usage of rectal foam\u002Fenema or treatment with adjuvant chemotherapy or radiotherapy\n14. Patient is currently on parenteral diet\n15. Patient is planned to undergo MRI procedure during usage of the wireless capsule\n16. Patient is working in a professional healthcare facility (e.g. hospital, dental office, emergency room), military area (e.g. submarine, near radar installation), or heavy industrial area (e.g. power plants, automotive, mining, refineries) during the duration of the clinical investigation\n17. Patient is pregnant, breastfeeding, actively trying to get pregnant or had recent childbirth in last 6 months\n18. Patient cannot discontinue medication that affects gastrointestinal transit time and\u002For pH for at least 3 days before and during the study (and 4 weeks for weekly\u002Flong-acting GLP-1 analogues such as Saxenda, Ozempic, Wegovy, Mounjaro). This includes opioids (e.g., morphine, codeine), proton pump inhibitors (e.g., omeprazole, esomeprazole, pantoprazole), H2-receptor antagonists (e.g., cimetidine, famotidine), antacids, sucralfate, prokinetics (e.g., domperidone, metoclopramide), antidiarrheal agents (e.g., loperamide), antibiotics, probiotics and prebiotics.\n19. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.",{"count":54,"type":22},51,"OBSERVATIONAL","The goal of this clinical trial is to characterize gastrointestinal digestion and physiology in patients after bariatric surgery, or people living with obesity. The main question it aims to answer is: what is the status of gastrointestinal digestion and physiology after bariatric surgery? Participants will have two study visits: 1) participants will undergo collection of gastrointestinal samples and 2) participants will ingest an ingestible capsule that measures multiple physiological parameters along the gastrointestinal tract.",[58,28,59,60],"Bariatric Surgery","Sleeve Gastrectomy","Obesity & Overweight",[62,63],"Gastro-intestinal aspiration","ingestible telemetric capsule","RECRUITING","2026-01-15",{"date":67,"type":37},"2026-01-20",{"date":69,"type":22},"2026-01-10",{"date":71,"type":22},"2027-07-01",{"name":73,"class":44},"Universitaire Ziekenhuizen KU Leuven",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100543060","phase-4-iv-iron-induced-hypophosphatemia-after-rygb-100543060","NCT06350955","IV Iron-induced Hypophosphatemia After RYGB","Intravenous Iron-induced Hypophosphatemia in Patients With Roux-en-Y Gastric Bypass: a Single-blind, Randomized Clinical Trial Comparing Iron Isomaltoside (Monofer®) and Ferric Carboxymaltose (Ferinject®)","IVORY","Inclusion Criteria:\n\n* Patients over 18 years\n* Signed informed consent\n* Patients with previous RYGB surgery performed \\> 12 months ago\n* Failed response to oral iron supplementation\n* Established diagnosis of iron deficiency by ferritin \\\u003C 50 ug\u002Fl or serum ferritin ≤100ug\u002Fl and low transferrin saturation (TSAT) ≤ 30%\n* Normal phosphate blood level (0.8 - 1.45 mmol\u002Fl) before infusion\n* Normal magnesium blood level (0.65-1.05 mmol\u002Fl)\n* Outpatient\n\nExclusion Criteria:\n\n* \\- Patients with known hypersensitivity to iron preparation and\u002For anaphylaxis from any cause\n* Patients for whom a treatment with one of the IV iron is contra-indicated (based on product summary of product characteristics)\n* Women who are pregnant or breastfeeding\n* Intention to become pregnant during the course of the study\n* Renal failure, chronic kidney disease stage 3b or worse (eGFR ≤ 45 ml\u002Fmin\u002F1.73m2)\n* Patients who received IV iron infusion during the last 3 months before screening\n* Treatment with erythropoietin or erythropoietin-stimulation agents, red blood cell transfusion within the last 3 months prior to screening\n* Alcohol or drug abuse within the past 6 months\n* Planned surgical procedure within the clinical trial period\n* Surgery under general anaesthesia within the last 3 months prior to screening\n* Hyperparathyroidism\n* Kidney transplantation\n* Inability to follow study procedures or give informed consent\n* Use and inability to stop from V0 to study end, phosphate supplementation (except daily multivitamin preparation recommended after bariatric surgery; the exact amount of phosphate and iron supplementation in the daily multivitamin will be recorded)\n* Osteoporosis drug therapy (bisphosphonates, denosumab or selective oestrogen receptor modulators).\n* Patient who refuses to be informed of incidental discoveries that may contribute to the prevention, diagnosis, and treatment of existing or probable future illnesses.","99 Years",{"count":84,"type":22},94,[86],"PHASE4","The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).",[89,90],"Hypophosphatemia","Roux-en-Y Gastric Bypass","2024-08-19",{"date":93,"type":37},"2024-08-20",{"date":95,"type":37},"2024-05-02",{"date":97,"type":22},"2026-06",{"name":99,"class":44},"Lucie Favre","Roux En Y Gastric Bypass"]